Microneedle patch in the race for COVID-19 vaccine

SOPHIA ANTIPOLIS, France – August 24, 2020 | The race to find a COVID-19 vaccine has highlighted several microneedle technologies for their advantages over common parenteral injections. Microneedles have shown immense potential, since they can efficiently, painlessly and safely deliver a vaccine through the skin. Microneedles reach the underlying dermis and epidermis, rich in antigen[…]

COVID-19 markers test using a microfluidics technology developed by Optofluidic Bioassay

SOPHIA ANTIPOLIS, France – April 28, 2020 | According to Optofluidic Bioassay, COVID-19 antibody testing which is portable, fast, cheap and highly precise could be possible with a microfluidic device invented by the company. Optofluidic Bioassay was founded in 2015 as a spin-off of the University of Michigan. The company was identified as relevant microfluidics[…]

Abcellera’s patent involved in its collaboration with Gilead in infectious disease

SOPHIA ANTIPOLIS, France – June 14, 2019: Abcellera’s patent involved in its collaboration with Gilead in infectious disease. AbCellera has announced a partnership with Gilead to discover antibodies for infectious disease. AbCellera will apply its expertise in single-cell screening of natural immune sources to generate rich panels of antibody candidates for evaluation by Gilead. Gilead[…]

Applied Materials may enter the field of next-generation sequencing

SOPHIA ANTIPOLIS, France – May 6, 2019: Nanopore sequencing is one of the next-generation sequencing (NGS) technologies believed to be capable of revolutionizing DNA analysis. Nanopore sequencing is performed using an electrical detection method, which generally includes transporting a sample through the nanopore, which is immersed in a conducting fluid, and applying electric potential across[…]